MSD
-
【Product for Licensing】T-cell engager (TCE), bispecific, trispecific, and multispecific products are available
If you are interested in similar assets, please contact DrugTimes BD Team at BD@drugtimes.cn asap. Many thanks!~
-
Merck Halts Two Phase III Clinical Trials
Drug development is not easy, and we pay tribute to the heroes of innovative drug development!
-
As the 10th anniversary of approval approaches，Keytruda adds ‘potential’ performance to Merck
DrugTimes will follow up on this subject. Please stay tuned
-
Morphic’s stock prices soar by 75%! Eli Lilly invests an additional $3.2 billion in the autoimmune field
DrugTimes will present more reports timely. Please stay tuned
-
8 Key Highlights! What Do Global Pharma Industry BD and M&A Trends Forecast for 2024?
Where Pharma is Investing for the Future of Medicine: Biopharma Deal Making in 2024
-
Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Warmest congratulations to Merck and Orion, and to prostate cancer patients!
-
TOP PHARMAS BY 2024 PIPELINE SIZE
For more info, please visit https://www.drugtimes.cn/english-content
-
Is it too early for Akeso and Summit to celebrate? Merck executive comments on the explosive news that Keytruda has been successfully challenged
Just our two cents. All comments, including criticisms, are warmly welcome. Thank you all very much!
-
After ten years, Merck returns to the field of ophthalmology with a $3 billion investment!
Congratulations to Merck and EyeBio!
